Premium
Localized 1 H NMR measurements of 2‐pyrrolidinone in human brain in vivo
Author(s) -
Hyder Fahmeed,
Petroff Ognen A.C.,
Mattson Richard H.,
Rothman Douglas L.
Publication year - 1999
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/(sici)1522-2594(199905)41:5<889::aid-mrm6>3.0.co;2-r
Subject(s) - vigabatrin , in vivo , human brain , occipital lobe , nuclear magnetic resonance , homonuclear molecule , chemistry , epilepsy , metabolite , nuclear magnetic resonance spectroscopy , anticonvulsant , neuroscience , stereochemistry , biochemistry , psychology , biology , physics , microbiology and biotechnology , organic chemistry , molecule
Localized 1 H NMR homonuclear J editing spectroscopy was used to measure the concentration of 2‐pyrrolidinone (PRDN) in the human occipital lobe of five normal and six epileptic subjects taking vigabatrin. PRDN is a lactam cyclization product of γ‐aminobutyric acid (GABA). From a localized volume of 13.5 cm 3 in the occipital cortex, the concentration of PRDN ranged from 0.2 to 0.3 μmol/g in normal subjects, whereas in epileptic subjects on vigabatrin PRDN was elevated to 0.6 ± 0.1 μmol/g. The elevated PRDN in patients on vigabatrin was in accord with raised GABA levels compared with normals. 1 H NMR measurements of PRDN will be important in assessment of the role of this metabolite for improved seizure control. Magn Reson Med 41:889–896, 1999. © 1999 Wiley‐Liss, Inc.